These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 19889066

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
    Song C, Kim YS, Hong JH, Kim CS, Ahn H.
    BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
    [Abstract] [Full Text] [Related]

  • 5. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ, Brandt D, Schour L, Hill DR.
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [Abstract] [Full Text] [Related]

  • 6. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC, Sadetsky N, Chen MH, Carroll PR, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):36-9. PubMed ID: 19233568
    [Abstract] [Full Text] [Related]

  • 7. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
    Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A.
    Int J Radiat Oncol Biol Phys; 2005 Dec 01; 63(5):1455-62. PubMed ID: 16169682
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.
    J Natl Cancer Inst; 2007 Oct 17; 99(20):1516-24. PubMed ID: 17925537
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D, Tyldesley S, Pickles T, Prostate Cohort Outcomes Initiative.
    Cancer; 2008 May 01; 112(9):1941-8. PubMed ID: 18338814
    [Abstract] [Full Text] [Related]

  • 13. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2010 Apr 01; 76(5):1439-44. PubMed ID: 19540066
    [Abstract] [Full Text] [Related]

  • 14. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
    Liauw SL, Fricano J, Correa D, Weichselbaum RR, Jani AB.
    Cancer; 2009 Apr 15; 115(8):1784-90. PubMed ID: 19208426
    [Abstract] [Full Text] [Related]

  • 15. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
    D'Amico AV, Saegaert T, Chen MH, Renshaw AA, George D, Oh W, Kantoff PW.
    Cancer; 2002 Jul 15; 95(2):275-80. PubMed ID: 12124826
    [Abstract] [Full Text] [Related]

  • 16. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA, Skowronski RY, Coen JJ, Grocela JA, Hirsch AE, Zietman AL.
    Int J Radiat Oncol Biol Phys; 2008 Aug 01; 71(5):1302-8. PubMed ID: 18262732
    [Abstract] [Full Text] [Related]

  • 17. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA.
    Cancer; 2009 Oct 01; 115(19):4470-6. PubMed ID: 19637339
    [Abstract] [Full Text] [Related]

  • 18. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1048-55. PubMed ID: 15001244
    [Abstract] [Full Text] [Related]

  • 19. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
    Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll PR.
    Urology; 2007 Jul 15; 70(1):106-10. PubMed ID: 17656218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.